Injection
Phase 2PRESERVE recruiting
← Therapy pipeline
Investigational · Obesity development
ALV-100
Alveus Therapeutics
A fusion protein combining GLP-1 receptor agonism with GIP receptor antagonism.
GLP-1GIP
Other study areas
Weight maintenance / switching
Selected program areas, not approvals. See the full profile for individual trials.Obesity stagePhase 2
Phase 1Phase 2Phase 3Regulatory review
Updated as of November 2026SponsorAlveus Therapeutics
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
Results availability
No numerical results shown
Phase 2 clinical efficacy results are pending.
Mechanism at a glance
GLP-1GLP-1Receptor agonist
GIPGIPReceptor antagonist
GCGglucagon—
AMYamylin—
OTHOther targets—
Obesity stage by formulation
Milestone → next
Latest: Alveus announced first dosing in Phase 2 PRESERVE on September 14, 2026. The current registry lists the study as recruiting.
Next: PRESERVE weight-maintenance and safety results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
PRESERVE
Weight-loss maintenanceStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Phase 2, estimated 220 participants; 24-week maintenance study after at least 10% weight loss on prior incretin therapy. Current registry describes five regimen arms; no results posted.